{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination can sensitize tumors to anti-PD-L1 checkpoint blockade and improve control when combined.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        },
        {
          "quote": "Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.",
          "line_ref": "L14"
        }
      ],
      "caveat": "The human association is observational, and preclinical efficacy may not generalize to all human tumor settings."
    },
    {
      "claim_id": "C02",
      "claim": "mRNA vaccination is associated with a broader antigenic landscape and greater immune-cell presence in tumors.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Broader antigen display after intratumoral mRNA vaccination",
          "line_ref": "L28"
        },
        {
          "quote": "Increased immune infiltration with combination therapy",
          "line_ref": "L33"
        }
      ],
      "caveat": "These quantitative readouts are summary values and mechanistic effects were not uniformly identical across all models."
    },
    {
      "claim_id": "C03",
      "claim": "Type I interferon signaling is a required mechanism in this sensitization process in the reported experiments.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        },
        {
          "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        }
      ],
      "caveat": "Causality is best supported in mechanistic mouse experiments and has not been proven as the dominant driver clinically."
    },
    {
      "claim_id": "C04",
      "claim": "Retrospective human data suggest a survival advantage for vaccinated patients receiving immune checkpoint blockade.",
      "strength": "tentative",
      "evidence": [
        {
          "quote": "Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment",
          "line_ref": "L30"
        },
        {
          "quote": "The human analysis is retrospective and non-randomized; residual confounding is likely.",
          "line_ref": "L49"
        }
      ],
      "caveat": "Causal interpretation is limited by non-randomized design, variable vaccination timing, and heterogeneity in tumor types and treatment history."
    }
  ]
}